Clinical trials: Acute Moderate-to-severe Pain
Pulmonary Disease, Chronic Obstructive
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a…
- Trial name
- NCT03345407
- Testing
- Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg
- Where
- 161 sites in United States, Argentina and 14 more
- Volunteers
- 943 people
- Sponsor
- GlaxoSmithKline
Pain, Acute
Efficacy and Safety of Penthrox® Combined With a Standard Analgesia (SoC) in Adult Patients Admitted to the Emergency Department With Moderate to Severe Pain Associated With Trauma
A phase 4 randomised, double-blind study to assess the efficacy and safety of Penthrox® used from the outset in multimodal analgesia, in combination with the standard analgesic protocol used in the department, for conscious adult…
- Trial name
- Pen ASAP (NCT03798899)
- Testing
- Methoxyflurane, Normal Saline
- Where
- 8 sites in France
- Volunteers
- 360 people
- Sponsor
- Mundipharma SAS
Covid19, ARDS
Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome
Non-invasive ventilation can allow to avoid intubation and improve outcomes in moderate-to-severe COVID-19-associated acute respiratory distress-syndrome (ARDS).
- Trial name
- COVID-NIV (NCT04667923)
- Testing
- Respiratory monitoring, Respiratory muscles ultrasound, Electro impedance tomography
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Chronic Obstructive Pulmonary Disease (COPD)
Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract
The colonization of potential pathogenic bacteria in lower respiratory tract is thought to be accountable for acute exacerbation in subjects with moderate to severe COPD.
- Trial name
- PAEAN (NCT03449459)
- Testing
- oral probiotics, aerosol inhaled amikacin, combined vaccination
- Where
- 3 sites in China
- Volunteers
- 144 people
- Sponsor
- Shanghai Zhongshan Hospital
Erythema Nodosum Leprosum
Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction
Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world.
- Trial name
- NCT07172659
- Testing
- Dovramilast, Prednisolone, Thalidomide
- Where
- 6 sites in United States, Benin and 4 more
- Volunteers
- 45 people
- Sponsor
- Medicines Development for Global Health